1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

MoonBiotech

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2015

Location

Guangzhou Guangdong China

Primary Industry

Biotechnology

About

Established in 2015 and based in Guangzhou, China, MoonBiotech operates as a microbial resource service provider that focuses on commercializing microbial resources. The company's core team graduated from the Chinese Academy of Sciences, Peking University, University of Würzburg, Germany, etc. It acquired certifications such as ISO9001 and ISO14001, and has obtained 56 patents. In July 2024, MoonBiotech raised CNY 300 million in series C+ funding from new investor Guotou Juli Investment Management. The company mainly uses microbial separation and cultivation technology to discover, preserve and identify microbial diversity resources with development value. It built a microbiological technology platform (Culture-to-Product platform) which provides microbiological products for customer. MoonBiotech also provides bio-based products and solutions for bio-agriculture, biopharmaceuticals, microbial proteins and other fields. In the biopharmaceutical sector, the company's pipeline of drug products includes multiple therapeutic areas such as tumours, obesity, and non-alcoholic fatty liver disease. In bio-agriculture sector, it provides biochemical pesticides and solutions for nematode and foliar diseases. The company generates revenue by commercialization of microbial applications, and providing bio-based products and solutions for bio-agriculture, bio-medicine, microbial proteins and other fields. The company plan to use the series C+ funding to promote the large-scale production and commercialization of innovative biological products, as well as to expand the company's own commercial microbial strain library and component library, and improve the biomanufacturing technology platform.
Current Investors
Yuexiu Industrial Investment Funds Management, HighLight Capital, Suzhou TechWisdom Capital

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Healthcare IT, Oncology/Cancer Treatment
Website
www.moonbio.com
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.